

APAC Healthcare Pulses with Digital Innovation

May 1, 2026 | Analysis | By Ayesha Siddiqui

Gone are the days when healthcare simply meant pills and potions. Today, every step of the journey is getting digitised. Booking a GP appointment, consulting a doctor, tracking recovery, and in some cases even receiving therapy, all of it can now happen on a screen. Digital health today is a mix of multiple layers. There's telemedicine making access easier, AI stepping into areas like cancer diagnostics, and digital therapies that are starting to act like actual treatment, not just support tools. Let's look at the key segments of digital health, the players building these solutions, the products they offer, and most importantly, who is actually using these technologies.



Digital health is now a key part of modern medicine. Since app stores emerged in 2008, more than one million consumer digital health applications have been developed, and over 360 software-based therapeutic tools have been used by patients and providers globally, according to an IQVIA report. In the Asia Pacific, the ecosystem includes 2,673 ventures, with the market projected to grow from about \$72 billion in 2024 to nearly \$500 billion by 2033.

Let's look at the key segments of digital health. These include telemedicine and virtual care, AI in cancer diagnostics, wearables, and electronic health records and hospital IT systems. We will also look at the companies building these solutions, the products they offer, and who is using them, from patients and clinicians to hospitals, insurers, and governments.

Telemedicine and virtual care

Companies: Practo (India), Ping An Good Doctor (China), Halodoc (Indonesia), and Doctor Anywhere (Singapore)

Products: Full-stack platforms combining teleconsultation, e-prescriptions, diagnostics, hospital systems and medicine delivery.

Users: Patients, doctors, hospitals, insurers, employers, and governments drive adoption

If there's one segment where digital health has seen massive adoption in Asia-Pacific, it is telemedicine. The region now hosts over 3,700 startups, with the market projected to reach \$105.82 billion by 2034. Almost every major market has a dominant player, from Practo in India to Ping An Good Doctor in China, and Halodoc in Indonesia to Doctor Anywhere in Singapore.

Doctor Anywhere is a Singapore-based platform serving 2.8+ million users across Southeast Asia, offering 24/7 consultations, medication delivery, health screenings, and specialist care, while also supporting 1,000+ corporate clients and 30+ insurers through a network of 3,600+ healthcare professionals and 28+ clinics and pharmacies.

Practo has served 5 crore+ patients across 640+ cities with 5 lakh+ verified doctors, supported by 4 crore+ data points and 1,000+ audited establishments, while also providing SaaS products like Ray, used by 10,000+ clinics, and Insta, deployed across 1,200+ facilities, with clients including Apollo Health and Lifestyle, VPS Healthcare, and Motherhood.

Ping An Good Doctor serves 440+ million users through an integrated model combining AI-assisted consultations and 24/7 doctors, supported by a network of 50,000+ medical professionals, 3,000+ hospitals, and 200,000+ pharmacies, while also serving 6,700+ corporate clients and 2,100+ enterprises with services including consultations, referrals, medication delivery, and corporate healthcare support.

It is also worth noting that beyond individual users, these platforms work with corporates and insurers, supported by thousands of enterprise accounts and partnerships. Patients are the most visible users, accessing consultations, prescriptions, and follow-ups. Doctors use these platforms to extend care beyond clinics. Hospitals use telemedicine to expand reach and manage patient load. Insurers use it to reduce costs. Employers offer it as part of the benefits. Governments deploy it to improve access at scale.

Another clear trend is product expansion. These platforms do not stop at teleconsultation. They extend into diagnostics, pharmacy, hospital software, and care navigation, building an end-to-end system.

Then there are companies moving into continuous and preventive care, shifting from episodic interactions to ongoing health management.

“Modern healthcare remains largely reactive, treating disease after symptoms appear rather than detecting risk early. At the same time, patients navigate fragmented systems where diagnostic data is spread across providers, and doctors face time constraints that limit deeper risk assessment. This creates a gap where risks are often missed or identified too late, not due to lack of data, but due to limited infrastructure to interpret it,” observed **Marc Hermann, CEO and Co-Founder of Everlab**.

Everlab addresses this by building an integrated, proactive care model that combines diagnostics, scans, and advanced testing into a single platform, using AI to analyse health data at scale and enable doctors to focus on clinical decision-making and patient care.

“Our primary users are individuals seeking a more informed, preventative approach to their health - from the general population curious about their health, high-performing professionals, to those with specific risk factors or family history. Alongside this, we partner with leading organisations, including Bain & Company, BHP and Woolworths to support corporate health at scale. In that context, Everlab functions as both a preventative healthcare platform and a strategic tool for improving workforce health, reducing long-term risk, and supporting performance,” said Hermann.

Everlab has processed millions of biomarkers and analyses over 200,000 diagnostic reports each month, with around 25 per cent showing abnormalities and 2.5 per cent identifying serious, previously undetected conditions such as blocked arteries and early-stage cancers. With 10,000+ members, 100+ clinicians, and 40,000+ consultations delivered, it reflects a model built on early detection and continuous care.

Wearables

Companies: Aevice Health (Singapore), Respiree (Singapore/Australia), Nutromics (Australia), ResMed (Australia)

Products: Wearable sensors, smart stethoscopes, continuous biomarker monitoring platforms, and AI-enabled remote patient monitoring systems

Users: Clinicians and hospitals use them for monitoring; patients with chronic conditions use them for continuous care at home

Wearables have moved beyond consumer fitness tracking into clinical monitoring, with devices now used for continuous, real-time patient care across hospital and home settings.

Aevice Health (Singapore), a spin-off from Nanyang Technological University, focuses on respiratory care through its wearable stethoscope, AeviceMD, and patient management platform. The system continuously monitors biomarkers such as

respiratory rate, heart rate, and wheezing, using algorithms to detect early signs of deterioration in conditions like asthma and COPD. It is approved by the Health Sciences Authority and cleared by the U.S. Food and Drug Administration, and is deployed in hospitals and care facilities to support remote monitoring and reduce readmissions.

Another example is Respiree (Singapore/Australia), which provides a chest-worn wearable (RS001) that tracks respiratory rate and other vitals, integrated with its 1Bio cloud platform for real-time monitoring. Its AI layer analyses patient data to prioritise alerts and reduce noise, while integration with electronic health records supports clinical workflows. The system is used by clinicians in hospitals, including non-ICU settings, and in home care for chronic conditions. Respiree operates across the US, Europe, Australia, and parts of Asia. The firm has partnered with Roche Diagnostics and Philips to advance monitoring capabilities and support hospital-at-home programmes.

ResMed (Australia) focuses on connected devices and digital health platforms for sleep apnea, COPD, and other respiratory conditions, enabling remote monitoring and home-based care.

Another company, Nutromics (Australia), is building a wearable platform for continuous real-time monitoring of drugs and biomarkers. Its first product focuses on improving vancomycin dosing in hospitals and reducing toxic side effects, while a second targets sepsis detection and management. The company is preparing for its Series B round and a planned U.S. commercial launch in 2027.

AI in cancer diagnostics

Companies: Lunit (South Korea), Qure.ai (India), Harrison.ai (Australia) are leading deployments across imaging, pathology, and integrated AI platforms.

Products: Imaging AI (e.g., qXR), digital pathology tools, and platform-based solutions that integrate multiple algorithms into hospital workflows.

Users: Hospital networks, diagnostic centres, radiology groups, life sciences companies, and global healthcare institutions

AI is addressing one of the most persistent gaps in healthcare: the delay between disease onset and timely diagnosis. In conditions such as tuberculosis and lung cancer, even small delays in detection can significantly affect treatment outcomes. Around 180 companies are working on AI in medical diagnostics.

Adoption is led by institutions such as public health systems, hospital networks, diagnostic centres, radiology groups, and life sciences companies, while the end users are clinicians, including radiologists, pulmonologists, emergency physicians, and public health workers who integrate these tools into routine workflows.

A key example is India's Qure.ai. "Our AI-powered solutions are built to enable more consistent interpretation of medical imaging, allowing earlier identification of abnormalities and better prioritisation of high-risk patients. The result is faster clinical decision-making and more timely intervention. This is particularly critical in public health and resource-constrained settings, where access to specialists is limited and diagnostic backlogs are common. Bringing AI closer to the point of care supports frontline teams in making informed decisions and ensures appropriate follow-up," stated **Ankit Modi, Founding Member & Chief Strategy and Growth Officer, Qure.ai.**

Its chest X-ray solution, qXR, is used in large-scale lung screening programmes, including in Goa (India), where over 1.06 lakh scans across 18 government facilities identified 10,564 lung nodules, including 1,619 high-risk cases, leading to 18 confirmed lung cancer diagnoses and a 50 per cent reduction in time to diagnosis.

"Today, our solutions are deployed across 105+ countries and 5,200+ healthcare sites, reflecting a shift from pilot use cases to integration into routine healthcare delivery at scale. Looking ahead, we are hopeful about the momentum building in Telangana (India), where AstraZeneca has signed an MoU with the state government to deploy our AI-powered lung cancer screening across 20 public healthcare facilities. What encourages us is the trust that governments and health systems are placing in this approach. That, for us, suggests AI-driven screening has a meaningful role to play in how India addresses some of its most pressing public health challenges," said Modi.

Apart from advances in diagnostics, companies are addressing operational challenges in radiology, where workforce gaps of up to 30 per cent and rising imaging volumes are putting systems under pressure.

"AI is often positioned as the solution. But in practice, adopting radiology AI has come with its own set of challenges. Every new decision-support AI that is being adopted by the radiology team typically means another integration, another contract, another security review. Instead of simplifying things, it's created a fragmented, complex IT environment that's difficult to scale. That's exactly the problem we set out to solve with the Harrison Open Platform. Rather than asking hospitals to manage dozens of radiology AI solutions, we provide a single integration point called Harrison Open Platform to access all the radiology AI," said Ben Austin, Chief Product Officer, Harrison.ai.

He added, "Through this, clinicians can use Harrison's own comprehensive suite alongside a carefully curated ecosystem of specialist partner algorithms for various use cases. Each partner brings expertise across different imaging domains (MRIs, mammography and ultrasound, etc.), helping healthcare organisations evaluate and adopt AI tools that align with their specific workflows, priorities, and patient populations."

The zero-markup model means healthcare organisations pay only for the AI tools they use, without the 30–60 per cent platform fees seen in traditional models. This allows vendors to maintain direct relationships and focus on innovation, while hospitals select algorithms based on clinical value and ROI rather than vendor lock-in. The Harrison.ai Open Platform includes partners such as Lunit, along with Lucida Medical, AZmed, Nicolab, Radiobotics, CoLumbo, AIRamed, Koios Medical, Nanox AI, and Us2.ai.

Electronic Health Records (EHRs) and Health Information Systems

Companies: Telstra Health (Australia), Swisslog Healthcare (Switzerland), Heidi Health (Australia), Zeya Health (Singapore)

Products: EHR and hospital information systems, AI-driven clinical documentation and workflow tools, and patient engagement platforms for scheduling, reminders, and communication

Users: Hospitals and clinics as primary adopters, with clinicians, administrative staff, and patients using these systems for care delivery, operations, and interaction

Digital health not only improves the patient experience but is also being used to make hospital administration and clinic operations more efficient. Companies are addressing key bottlenecks in healthcare delivery, particularly around operational inefficiencies, administrative burden, and patient safety.

One of the most important challenges hospitals face today is the growing administrative burden. Clinics spend significant time managing patient communications, scheduling, reminders, follow-ups, and coordination across multiple channels, creating inefficiencies, increasing staff workload, and reducing the time clinicians can spend delivering care.

Zeya Health addresses this problem by acting as an AI-powered operational layer for clinics. "Our platform automates patient engagement workflows — such as appointment scheduling, reminders, follow-ups, and enquiries — across channels like WhatsApp, website chat, email, and social messaging.

Rather than replacing clinic staff, Zeya augments the front desk and care teams, removing repetitive administrative tasks so they can focus on patients," said **Agastya Samat, CEO, Zeya Health**.

He added, "Our primary customers are outpatient healthcare providers, including GP clinics, specialist clinics, dental practices, physiotherapy centres, and aesthetics clinics. Our primary users include:

Front desk and administrative staff managing patient communications; Clinic managers overseeing operations and scheduling, and patients interacting with the clinic through messaging channels."

Today, 40+ clinics are using Zeya Health, including groups such as Elite Dental Group and EDGE Healthcare. In the past six months, clinics using the platform have reported up to a 50 per cent reduction in administrative workload, a 30 per cent drop in missed patient messages, 40 per cent faster response times to patient enquiries, and 20 per cent fewer last-minute cancellations due to automated reminders.

Another example is Australia-based Heidi Health, an AI care partner designed to take on administrative tasks and support clinicians across workflows, allowing them to focus more on patient care. "Heidi improves patient care by giving clinicians more time to be present with patients, improving the quality and clarity of clinical documentation, and enabling better follow-up through structured records and real-time access to relevant medical evidence," said **Dr Thomas Kelly, CEO & Co-Founder, Heidi**.

He added, “Our starting point was ambient AI scribing. Heidi listens during the consultation and generates accurate, structured clinical notes in real time, which means less time typing, less time catching up afterwards, and better continuity of care. From there, we’ve expanded into a broader clinical workflow platform. That includes Heidi Evidence, which brings trusted medical literature into the point of care; Comms, which supports clinical correspondence and follow-up; and Remote, our first hardware product, built to deliver reliable consultation audio capture in real-world settings. The real value comes from how these products work together as one connected platform. Each one reinforces the others with richer context and better data, which significantly improves Heidi’s impact on the clinical encounter. A core design principle is our clinician-led development model. Heidi is built and continuously refined by practising doctors to ensure it reflects real-world clinical complexity rather than theoretical workflows. This has driven strong adoption in high-pressure environments, including emergency departments, where speed, accuracy, and reliability are critical.”

Its primary users are clinicians, and its customers range from individual practitioners to large healthcare organisations, hospitals, and health systems. The company supports over two million consultations per week, operates in 110 languages across 190 countries, and has grown to more than 400 employees, with strong clinical representation across the team.

Heidi Health’s 2025 Impact Report highlights measurable efficiency gains, including 59 minutes of capacity released per clinician per day, 97 per cent of clinicians reporting good or excellent document quality, 98 per cent willing to continue using the platform, an 87 per cent reduction in overtime, and a 99 per cent patient acceptance rate.

“Our long-term vision is to become the foundational AI layer across global clinical practice. Rather than automating isolated tasks, the goal is to embed an AI Care Partner across the full care continuum. Only then can we double the world’s healthcare capacity,” said Dr Kelly.

Another key concern is medication errors, which remain a leading patient safety issue globally, with the World Health Organisation estimating their cost at around \$42 billion annually.

“Swisslog Healthcare is addressing one of the most pressing and universal challenges in modern healthcare: how to deliver consistently safe, high-quality care in increasingly complex hospital environments with limited resources. We view medication management as a fundamental pillar of patient safety. Our focus is on ensuring that medications are managed and delivered with the highest levels of safety, accuracy, and consistency throughout the hospital ecosystem. By reducing reliance on manual processes and introducing greater traceability and standardisation, we help healthcare providers reinforce the basics of safe care, ensuring the right medication reaches the right patient at the right time, every time.” said **He PengHui, Managing Director, Swisslog Healthcare APAC.**

He added, “We partner with hospitals and healthcare systems to empower the people on the front lines. The real impact of our solutions is felt by pharmacists, nurses, and clinicians who rely on these systems daily to make critical decisions and deliver care efficiently and safely.”

Moving forward, digital health will continue to grow. IDC predicts that agentic AI, advanced analytics, and emerging technologies will deliver measurable gains in productivity, patient experience, and clinical outcomes.

Ayesha Siddiqui